Skip to content
Open access · OA via Europe PMC

Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.

Gadhave DG, Jadhav AB, Waghamode NB, Khot S, Khan R, Hole R, Dhobale SM, Aswar M, Paudel KR.

Advanced healthcare materials · 2026

Abstract

Aging is a significant risk factor of neurodegenerative disorders (NDs) such as Huntington's, Alzheimer's, Parkinson's, amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Although several clinical, neuroimaging, and biomarker-based diagnostic approaches are available for NDs, their limited sensitivity for early-stage detection, disease specificity, and prediction of disease progression continue to present significant clinical challenges, often resulting in delayed diagnosis and therapeutic intervention. According to previously published works, the preliminary pathological feature of such disorders is mitochondrial dysfunction(definition). This may lead to elevated oxidative stress, impaired mitophagy, unbalanced mitochondrial function, and bioenergetic failure. This review examines how mitochondria-targeted nanotherapeutic approaches can overcome these pathological barriers and improve therapeutic outcomes in aging-associated neurodegeneration. Targeted delivery of drug-loaded nanocarriers, such as gene-delivery, lipid-based, metallic, and polymeric nanoparticles, has emerged as a potential platform to deliver medication directly to defective mitochondria. It may increase mitochondrial biogenesis, maintain redox balance, and protect against neuronal degeneration. This work incorporates disease-specific mitochondrial pathology with current progress in targeted nanotherapeutics, age-associated delivery barriers, clinical revolution, and emerging artificial intelligence (AI)-enabled precision therapeutic approaches. Mitochondria-targeted nanotherapeutics depict a potential disease-modifying strategy for aging-related NDs. However, further advancements in targeting efficacy, scalable production, long-term safety, and clinical validation can facilitate a successful clinical revolution.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
Europe PMC
DOI
10.1002/adhm.71594
Canonical
link ↗
Fetched
2026-10-06 MST

Cite this

APA
DG, G., AB, J., NB, W., S, K., R, K., R, H., SM, D., M, A., &amp; KR., P. (2026). Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential. <em>Advanced healthcare materials</em>. https://doi.org/10.1002/adhm.71594
Vancouver
DG G, AB J, NB W, S K, R K, R H, et al. Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential. Advanced healthcare materials. 2026. doi:10.1002/adhm.71594.
BibTeX
@article{gadhave2026Mitoch, title = {Mitochondria-Targeted Nanotherapies in Aging Neurodegenerative Disorders: Emerging Prospects and Clinical Potential.}, author = {Gadhave DG and Jadhav AB and Waghamode NB and Khot S and Khan R and Hole R and Dhobale SM and Aswar M and Paudel KR.}, journal = {Advanced healthcare materials}, year = {2026}, doi = {10.1002/adhm.71594}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings